Among the gene differentially modulated by engineered EV-containing miR-125b produced by mesenchymal cells genetically modified to overexpress miR-125b we detected HX2 (hexokinase 2), which has been described as a miR-125b target in hepatocellular carcinoma [57], the transcription factor E2F3 and insulin-like growth factor I, whose expression has been found deregulated by miR-125b in bladder cancer [58,59], the anti-apoptotic protein Bcl-2, as previously evidenced in HCC [32], as well as CDC25A, a key mediator of cell cycle progression. The gene discussed is CDC25A; the disease is urinary bladder cancer.